SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary patency. SELUTION SLR™ DEB demonstrates real-world effectiveness and consistency across...
Read More Details
Finally We wish PressBee provided you with enough information of ( Cordis Announces Positive Results from Two Major Studies Demonstrating Durable Efficacy of SELUTION SLR™ Drug-Eluting Balloon in Complex Peripheral Artery Disease Patients )
Also on site :
- At least 59 Palestinians killed as Israel escalates Gaza bombardment
- Pope Francis’ funeral to stream on YouTube
- No Way: FBI Assesses That Venezuela Facilitating Migration of Gang Members to US